Zevra Therapeutics CEO sells 20,000 shares

The 20,000-share sale was made under a Rule 10b5-1(c) plan adopted March 25, 2026, after the October 10 RSU settlement.

(High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. President and CEO and director Neil F. McFarlane settled 50,000 restricted stock units for 50,000 common shares on October 10, 2026. Two days later, he sold 20,000 shares at a weighted average of $11.2474 per share in multiple trades priced from $11.07 to $11.36. The sale was made under a Rule 10b5-1(c) plan adopted March 25, 2026. The remaining 25% of the RSUs is scheduled to vest October 10, 2027, subject to the stated employment condition.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider McFarlane Neil F.

Role President and CEO

Sold 20,000 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F2, F3}	20,000	$11.2474	$225K
Exercise	Restricted Stock Unit ^{F1, F4}	50,000	$0.00	$0.00
Exercise	Common Stock ^F1	50,000	--	--

Holdings After Transaction: Restricted Stock Unit — 50,000 contracts (Direct); Common Stock — 417,225 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2. Adoption date of referenced 10b5-1(c) plan is: 03-25-2026
F3. This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4. 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.

Key Figures

Restricted stock units settled: 50,000 units Common shares acquired: 50,000 shares Shares sold: 20,000 shares +1 more

4 metrics

Restricted stock units settled 50,000 units October 10, 2026

Common shares acquired 50,000 shares Upon settlement of restricted stock units on October 10, 2026

Shares sold 20,000 shares October 12, 2026

Weighted average sale price $11.2474 per share Sale on October 12, 2026

Key Terms

restricted stock unit, Rule 10b5-1(c) plan, weighted average sale price

3 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Rule 10b5-1(c) plan regulatory

"the sale made under a Rule 10b5-1(c) plan adopted March 25, 2026"

weighted average sale price financial

"The price reported reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When can Neil F. McFarlane’s ZVRA RSUs vest early?

The award’s shares will vest in full and become immediately exercisable upon a change of control of Zevra Therapeutics, Inc., or if Neil F. McFarlane is terminated without cause or resigns for good reason.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/13/2026 - 04:24 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:24 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McFarlane Neil F.

(Last)

(First)

(Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/10/2026		M		50,000	A	⁽¹⁾	437,225	D
Common Stock	10/12/2026		S⁽²⁾		20,000	D	$11.2474⁽³⁾	417,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0⁽¹⁾	10/10/2026		M			50,000	⁽⁴⁾	⁽⁴⁾	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Adoption date of referenced 10b5-1(c) plan is: 03-25-2026

3. This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR